<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260913071032N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-09-17</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Effectiveness of inspiratory muscle training versus conventional home-based breathing exercises in bariatric surgery patients at high risk for obstructive sleep apnea.</public_title>
      <acronym></acronym>
      <scientific_title>Effectiveness of Inspiratory Muscle Training Versus Conventional Home-based Breathing Training in Bariatric Surgery Patients at High risk For Obstructive Sleep Apnea: A Single-blind Randomized Clinical Trial.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/93254</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Patients are randomly assigned to either Group A or Group B using block randomization (block size of four) and sealed envelopes, Blinding description: The assessment of patient outcomes conducted before, during, and at the end of the intervention is performed by a trained assessor, while the other stages of the intervention are carried out by the researcher.</study_design>
      <phase>3</phase>
      <hc_freetext>Bariatric surgery, Obesity, Obstructive sleep apnea, Inspiratory muscle training.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In addition to standard post-bariatric surgery care, patients will undergo inspiratory muscle training using the PowerBreathe K5 device for 12 weeks. Training will commence at an intensity of 30% of Maximum Inspiratory Pressure (MIP) and—depending on the patient's condition and tolerance—will be increased to 40–60% of MIP over the course of 2 to 4 weeks. The sessions will consist of 30 breaths, organized into six sets of five breaths with a one-minute rest interval between sets; training will be conducted twice weekly under the supervision of a researcher in the sports medicine department. Intervention 2: Intervention group: In addition to standard post-operative care, patients will perform routine home-based breathing exercises, including diaphragmatic breathing, deep controlled breathing, and the use of an incentive spirometer for a period of 12 weeks. These exercises will be conducted twice weekly; patients will receive in-person instruction on the correct technique and will be provided with an instructional video and a logbook to record their practice. To monitor adherence, patients will be contacted by phone every 10 days.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The study protocol, research findings, and data analysis will be published as scientific articles upon completion of the study. Other study-related data and documentation will be made available to interested parties upon request—subject to feasibility—by contacting the principal investigator via email. Access to the data will be granted in compliance with principles of confidentiality and the protection of participants' information.

When:
Following the publication of the article, access to the mentioned data will be possible under the specified conditions.

To whom:
The data will be available to researchers affiliated with academic and scientific institutions.

Conditions:
Requests for access to de-identified individual-level data or other study documentation must be submitted via email to the principal investigator. Applicants must clearly state the purpose and intended use of the data or documentation in their request. Use of the provided data is permitted solely for scientific and research purposes, and any attempt to re-identify participants is prohibited. Statistical analyses and research activities aligned with the study's scientific objectives are permitted, provided that data confidentiality and research ethics principles are upheld. Furthermore, the publication or presentation of results derived from the data analysis must be conducted in a manner that precludes the identification of participants. Requests will be reviewed by the principal investigator, and upon approval, the requested data or documentation will be made available to the applicant.

Where to obtain:
Principal investigator of the study; requests for data or documentation can be made by emailing the principal investigator.

How to obtain:
The applicant's request is submitted via email to the principal investigator and must include the applicant's details, the purpose of obtaining the data or documentation, and the specific type of data or documentation required. The request is reviewed by the principal investigator, and upon approval, the requested de-identified data or documentation is provided to the applicant. Prior to the release of the data, the importance of maintaining confidentiality and refraining from any attempt to re-identify participants is emphasized.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Eghtesadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sina hospital, Hasan Abad Square, Imam Khomeini Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6634 8500</telephone>
        <email>maryam1991medicine@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Eghtesadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sina Hospital, Hasan Abad Square,</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6634 8500</telephone>
        <email>maryam1991medicine@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Undergoing bariatric surgery (Sleeve Gastrectomy or Gastric Bypass) 3 months prior
Pre-operative BMI ≥ 35 kg/m² or ≥ 30 kg/m² with obesity-related comorbidities
High risk for OSA based on a STOP-Bang score ≥ 3
Ability to perform breathing exercises and walk independently
Written informed consent to participate in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Prior definitive diagnosis of OSA and current use of CPAP or BiPAP, or initiation of CPAP during the study period
Serious post-bariatric surgery complications including, Anastomotic leak, Readmission or Severe infection
Uncontrolled pulmonary diseases including, Moderate to severe COPD, Uncontrolled asthma or Interstitial lung disease
Unstable cardiac disease including, Uncontrolled heart failure,	Unstable angina, Pulmonary hypertension, Uncontrolled hypertension (HTN)
Neurological or neuromuscular disorders affecting respiration
Pregnancy
Non-adherence to the training regimen (completing fewer than 70% of training sessions)
Absolute and relative contraindications for MIP testing and IMT use, including, Tympanic membrane disorders or a history of tympanic membrane surgery, history of pneumothorax, presence of pulmonary bullae, osteoporosis and high risk of rib fracture during IMT and MIP testing, patients with pacemakers or electronic/magnetic implants, intraocular diseases and disorders (glaucoma, retinal disorders, diabetic retinopathy, etc.), Large abdominal hernia requiring surgical repair, recent abdominal surgery (excluding bariatric surgery performed 3 months prior)
Severe orthopedic or neuromuscular diseases or disorders which prevent functional outcome assessment via the 6MWT</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In addition to standard post-bariatric surgery care, patients will undergo inspiratory muscle training using the PowerBreathe K5 device for 12 weeks. Training will commence at an intensity of 30% of Maximum Inspiratory Pressure (MIP) and—depending on the patient's condition and tolerance—will be increased to 40–60% of MIP over the course of 2 to 4 weeks. The sessions will consist of 30 breaths, organized into six sets of five breaths with a one-minute rest interval between sets; training will be conducted twice weekly under the supervision of a researcher in the sports medicine department.</i_keyword>
      <i_keyword>Intervention group: In addition to standard post-operative care, patients will perform routine home-based breathing exercises, including diaphragmatic breathing, deep controlled breathing, and the use of an incentive spirometer for a period of 12 weeks. These exercises will be conducted twice weekly; patients will receive in-person instruction on the correct technique and will be provided with an instructional video and a logbook to record their practice. To monitor adherence, patients will be contacted by phone every 10 days.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sleep Quality. Timepoint: Before intervention, 6 and 12 weeks after the start of the intervention. Method of measurement: Pitsburgh Sleep Quality Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Daytime Sleepiness. Timepoint: Before the intervention, six and twelve weeks after the intervention. Method of measurement: Epworth Sleepiness Scale.</sec_outcome>
      <sec_outcome>Submaximal functional performance. Timepoint: Before the intervention, six and twelve weeks after the intervention. Method of measurement: 6 Minutes Walk Test.</sec_outcome>
      <sec_outcome>Quality Of Life. Timepoint: Before the intervention, six and twelve weeks after the intervention. Method of measurement: Short Form Survey-36.</sec_outcome>
      <sec_outcome>Maximal Inspiratory Pressure. Timepoint: Before the intervention, six and twelve weeks after the intervention. Method of measurement: Power Breathe Device K5.</sec_outcome>
      <sec_outcome>Dynamic inspiratory muscle function. Timepoint: Before the intervention, six and twelve weeks after the intervention. Method of measurement: S-index.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-09-06</approval_date>
        <contact_name>Tehran University Of Medical Sciences, Sina Hospital</contact_name>
        <contact_address>School of Medicine of Tehran University of Medical Sciences, Poursina Street, Qods Street,  Enghelab Street Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
